Search

To characterize the growth of female authorship in the Society of Interventional Radiology (SIR) "Clinical Practice Guidelines" and "Reporting Standards" publications (henceforth called CPG) over a 15-year period and to identify ways to improve female representation. For CPGs covering "universal" topics, there was a near-significant increase in female authorship (n = 7/87, 8% in 2004-09 vs. 26/147,18% in 2014-19, P = 0.064), while for "specific" topics (which represent 73% of total CPG authorships) the increase was not significant (n = 30/253, 12% in 2004-09 vs. 55/378,15% in 2014-19, P = 0.39). While the incremental improvements are noteworthy, men are still more likely than women to author multiple CPGs, and female authorship has increased more slowly for CPG topics requiring content-expertise. [Extracted from the article]

Veins included were the inferior vena cava (IVC), bilateral common iliac veins (CIV), and bilateral external iliac veins (EIV). ISR occurred in 15.1% of IVC stents, 15.2% of CIV stents, and 18.4% of EIV stents. In both the CIV and EIV, Wallstents had a decreased risk of restenosis when compared to SMART stents (CIV: HR -3.0, P <0.005; EIV: HR -2.4, P = 0.02). [Extracted from the article]

To compare outcomes between low- and high-dose anticoagulation regimens following stent placement for nonthrombotic lower extremity venous disease. This suggests that short-term prophylactic anticoagulation or no anticoagulation may be as safe and effective as therapeutic anticoagulation following venous stent placement for nonthrombotic stenosis. [Extracted from the article]

To characterize long-term rates of in-stent restenosis and risk factors for in-stent restenosis after lower extremity venous stent placement. Patients with acute DVT (Hazard ratio (HR): 3.53, P = 0.015), acute on chronic DVT (HR: 3.93, P = 0.038), or chronic DVT (HR: 3.81, P = 0.0018) had increased risk of in-stent restenosis. Patients with thrombotic venous occlusions have a >3 times higher risk of in-stent restenosis than patients with nonthrombotic disease. [Extracted from the article]

Purpose: Recent drug shortages have required modifications to transarterial chemoembolization (TACE) techniques, and some trials have shown advantages to using drug-eluting bead (DEB) technology. We investigated whether the advantages of using DEBs over ethiodated oil emulsion extend to superselective catheterization and administration for the treatment of hepatocellular carcinoma (HCC). Materials and Methods: From March 2010 to March 2011, 232 patients with HCC were treated by superselective (segmental, subsegmental) TACE with one of 3 protocols, determined by the availability of materials at the time of treatment. 159 underwent conventional TACE using an emulsion of ethiodated oil with doxorubicin and/or cisplatin (cTACE), 47 received doxorubicin-eluting LC beads (DEBDOX), and 26 received doxorubicin-eluting Quadraspheres (hqTACE). Clinical and laboratory toxicity were evaluated monthly, and objective radiographic response was evaluated at 3 months. Results: Lesion-based response rates in the cTACE, DEBDOX, and hqTACE groups were 65.4%, 63.8%, and 53.8%, respectively, and showed no significant differences. Fever and fatigue were slightly more common in the hqTACE group; clinical adverse events were otherwise equivalent. Changes in laboratory values were mild, expected and transient. Total doxorubicin administered in the DEBDOX group (median 75 mg) and hqTACE group (median 50 mg) were significantly higher than in the cTACE group (median 40 mg; p<0.001, p=0.009). No advantages were found for high-risk patients (bilobar disease, ECOG 1, Child-Pugh B, postsurgical recurrence), including for objective response, systemic toxicity, hepatotoxicity, and doxorubicin-related toxicity. The median cost of materials was $1531 for DEBDOX, $1443 for hqTACE, and $238 for cTACE, but the cost of cTACE materials has since more than doubled. Conclusion: Despite previous studies showing advantages to using DEBs over cTACE, when performed in a superselective manner, TACE using DEBs was more expensive and showed no significant advantages in efficacy or toxicity, probably due to the inherent optimized conditions of superselective catheterization. [Copyright &y& Elsevier]